P2RX3

Across TCGA pan-cancer cohorts, P2RX3 RNA differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of P2RX3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where P2RX3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types P2RX3 is over-expressed in tumor, although a few such as CHOL and LIHC show the opposite, repressed pattern.

KIRC, CHOL, and LIHC are the cancer types where P2RX3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in P2RX3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+0.264	<.001	12	view →
CHOL	All	All	−0.626	<.001	5	view →
LIHC	Male	II,III,IV	−0.336	<.001	5	view →
PAAD	Male	All	+0.695	.008	2	view →
LUAD	All	All	+0.096	.013	2	view →
THCA	Male	All	−0.068	.016	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

P2RX3–KIRC

Open the KIRC breakdown →